quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:04:04·43d
INSIDERFiling
Sarepta Therapeutics Inc. logo

President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 1,399 shares, decreasing direct ownership by 0.61% to 226,271 units (SEC Form 4)

SRPT· Sarepta Therapeutics Inc.
Health Care
Original source

Companies

  • SRPT
    Sarepta Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 28UpdateBarclays$20.00
  • Dec 9UpdateWedbush$32.00
  • Nov 5UpdateMizuho$26.00
  • Sep 22UpdateBMO Capital Markets$50.00
  • Jul 29UpdateBarclays$22.00
  • Jul 29UpdateBernstein$13.00

Related

  • PR2d
    Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
  • PR4d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • PR23d
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.
  • PR30d
    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
  • PR30d
    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
  • PR36d
    Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
  • PR39d
    Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022